TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Quoix, Élisabeth; V. Sequist, Lecia; Nemunaitis, John; Beck, Thaddeus; Jaśkiewicz, Piotr; Oster, Jean-Philippe; Scherpereel, Arnaud; Juhász, Erzsébet; Mark, Z.; Álvarez, Rosa; N. Waqar, Saiama; L. Potz, Joseph; Vrindavanam, Nandagopal; Melnyk, Anton; J. Ross, Helen; Limacher, Jean‐Marc

doi:10.1186/2051-1426-2-s3-o12

Public

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Published in Journal for ImmunoTherapy of Cancer • Jan 1, 2014

Authors:

Élisabeth Quoix

Lecia V. Sequist

John Nemunaitis

Abstract

Meeting abstracts TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor-associated antigen and interleukin-2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker for TG4010 efficacy

Subject

Medicine

Immunotherapy

MUC1

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!